ANI Pharmaceuticals (NASDAQ:ANIP) Hits New 12-Month Low – Time to Sell?

Posted by Stanley Muller on Sep 11th, 2026

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report)’s share price hit a new 52-week low during trading on Wednesday . The stock traded as low as $69.96 and last traded at $70.4450, with a volume of 9889 shares trading hands. The stock had previously closed at $70.23.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Canaccord Genuity Group decreased their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating on the stock in a report on Monday, August 10th. Leerink Partners began coverage on ANI Pharmaceuticals in a report on Wednesday. They set an “outperform” rating and a $104.00 target price for the company. Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 8th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 14th. Finally, Weiss Ratings cut shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $105.57.

Read Our Latest Research Report on ANI Pharmaceuticals

ANI Pharmaceuticals Trading Up 1.1%

The company has a market cap of $1.64 billion, a price-to-earnings ratio of 15.40 and a beta of 0.45. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The business’s fifty day simple moving average is $77.58 and its two-hundred day simple moving average is $78.25.

ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million during the quarter, compared to analysts’ expectations of $260.13 million. During the same period in the prior year, the firm earned $1.80 EPS. The business’s revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Insiders Place Their Bets

In other news, CEO Nikhil Lalwani sold 5,400 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $74.30, for a total transaction of $401,220.00. Following the transaction, the chief executive officer directly owned 344,489 shares of the company’s stock, valued at $25,595,532.70. This represents a 1.54% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the sale, the senior vice president owned 75,534 shares of the company’s stock, valued at approximately $5,816,118. The trade was a 4.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 21,425 shares of company stock valued at $1,687,370 in the last three months. 8.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Penn Capital Management Company LLC raised its stake in shares of ANI Pharmaceuticals by 2,058.9% in the 4th quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock valued at $10,858,000 after purchasing an additional 131,030 shares in the last quarter. CenterBook Partners LP acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at about $1,518,000. Jupiter Topco LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at approximately $6,597,000. NFJ Investment Group LLC acquired a new stake in ANI Pharmaceuticals in the second quarter worth $2,766,000. Finally, Walleye Capital LLC bought a new stake in ANI Pharmaceuticals in the 2nd quarter valued at about $8,784,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

About ANI Pharmaceuticals

(Get Free Report)

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.